000126809 001__ 126809
000126809 005__ 20241125101141.0
000126809 0247_ $$2doi$$a10.3390/diagnostics13111918
000126809 0248_ $$2sideral$$a134213
000126809 037__ $$aART-2023-134213
000126809 041__ $$aeng
000126809 100__ $$aAlfaro, Enrique$$uUniversidad de Zaragoza
000126809 245__ $$aDiagnosis and treatment of helicobacter pylori infection in real practice—new role of primary care services in antibiotic resistance era
000126809 260__ $$c2023
000126809 5060_ $$aAccess copy available to the general public$$fUnrestricted
000126809 5203_ $$aHelicobacter pylori (H. pylori) is a key agent in several upper gastrointestinal diseases. Treatment of H. pylori infection is the main strategy for resolving the associated gastroduodenal damage in infected patients and for the prevention of gastric cancer development. Infection management is becoming complex due to the increase in antibiotic resistance, which already represents a global healthcare problem. Resistance to clarithromycin, levofloxacin or metronidazole have forced the adaptation of eradication regimens in this new reality to reach the eradication rate target recommended in most international guidelines (>90%). In this challenging scenario, molecular methods are revolutionizing the diagnosis of antibiotic-resistant infections and the detection of antibiotic resistance and opening a path towards personalized treatments, although their use is not yet widespread. Moreover, the infection management by physicians is still not adequate, which contributes to aggravating the problem. Both gastroenterologists and mainly primary care physicians (PCPs), who currently routinely manage this infection, perform suboptimal management of the diagnosis and treatment of H. pylori infection by not following the current consensus recommendations. In order to improve H. pylori infection management and to increase PCPs’ compliance with guidelines, some strategies have been evaluated with satisfactory results, but it is still necessary to design and evaluate new different approaches.
000126809 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000126809 590__ $$a3.0$$b2023
000126809 592__ $$a0.667$$b2023
000126809 591__ $$aMEDICINE, GENERAL & INTERNAL$$b59 / 329 = 0.179$$c2023$$dQ1$$eT1
000126809 593__ $$aClinical Biochemistry$$c2023$$dQ2
000126809 594__ $$a4.7$$b2023
000126809 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000126809 700__ $$aSostres, Carlos
000126809 700__ $$0(orcid)0000-0001-5932-2889$$aLanas, Angel$$uUniversidad de Zaragoza
000126809 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000126809 773__ $$g13, 11 (2023), 1918 [16 pp]$$tDiagnostics$$x2075-4418
000126809 8564_ $$s611091$$uhttps://zaguan.unizar.es/record/126809/files/texto_completo.pdf$$yVersión publicada
000126809 8564_ $$s2721833$$uhttps://zaguan.unizar.es/record/126809/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000126809 909CO $$ooai:zaguan.unizar.es:126809$$particulos$$pdriver
000126809 951__ $$a2024-11-22-12:02:47
000126809 980__ $$aARTICLE